Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months...

Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months after commercial marketing began. Bloomberg's Andrew Berens says the company will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75, which is 70% below the current price. The move could pose risks for Arena's (ARNA -4.4%) Belviq, which is a competitor to Qsymia.

From other sites
Comments (6)
  • SivBum
    , contributor
    Comments (2710) | Send Message
    Cost for each pill is likely less than 2 cents. The pricing was too high. The volume payoff may just be the ticket to drive top line and cash flow. Should hear more tomorrow:


    MOUNTAIN VIEW, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (VVUS:$10.04,00$-0.30,... today announced that management will present an overview of the company at three investment conferences during the month of March 2013.


    The conference presentation schedule is as follows:


    Cowen and Company 33rd Annual Health Care Conference
    March 5, 2013, 8:00am EST
    Boston Marriott Copley Place
    Boston, MA
    4 Mar 2013, 10:47 AM Reply Like
  • user418
    , contributor
    Comments (264) | Send Message
    If VIVUS gave their pills away for free, no one would take them.
    4 Mar 2013, 12:22 PM Reply Like
  • nomis_simon
    , contributor
    Comments (162) | Send Message
    a little pissed that they might be in position to blow belviq away?? I think so
    4 Mar 2013, 01:07 PM Reply Like
  • slimbobway
    , contributor
    Comments (21) | Send Message
    Bridging the gap of $58 million monthly expense to make $2 million in sales will take more than discounting Qsymia. The doctors writing the prescriptions won't care. The free 2 week sample pack didn't bridge the gap. I will be buying VVUS at $6 when they actually get through REMS and can market and sell through pharmacies unless they go belly up first.
    4 Mar 2013, 12:27 PM Reply Like
  • KeitthatPC
    , contributor
    Comments (9) | Send Message
    Perhaps I'm not as educated as a few of the other individuals out here in regards to touting the stock of a few of the other players in the FDA approved or soon to be approved weight loss field, but I do hold two MA's and I have been on the founders managed program consisting of the combination of drugs making up Qsymia for over 10 plus years! Being of sound mind and body after 10 years and suffering no ill effects from that combination with excellent weight loss and Qsymia having the highest "Efficacy" of weight loss there is "NO way in hell I would count VIVUS down and out with Qsymia!!!
    user418 their pills are worth it with the least adverse affect on health and the highest efficacy of weight loss!!
    4 Mar 2013, 12:49 PM Reply Like
  • rt1
    , contributor
    Comments (65) | Send Message
    Andrew Berins of Bloomberg is full of hot air. This offer only applies to the first 30 days on the preferred dose.


    The Save Now! Program is a limited-time-only offer intended for new patients starting Qsymia™ (phentermine and topiramate extended-release) capsules CIV. New patients with a written prescription on or after March 1, 2013 can receive their first 30 days of the recommended dose of Qsymia (7.5 mg/46 mg) for no more than $75, subject to applicable terms and conditions.
    4 Mar 2013, 07:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs